2026 AGM Presentation
Filed with ASX · · 45 pages · English
Summary by 6ix AI
Arovella Therapeutics Limited has released the Chair’s address and CEO presentation for its Annual General Meeting, detailing the company's focus on developing its invariant Natural Killer T cell therapy platform. This filing serves to inform shareholders about the company's progress and governance decisions during the AGM.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Arovella Appoints CEO
- Complete tumour clearance in gastric cancer animal study
- First Patient Dosed with ALA-101
- Quarterly Activities/Appendix 4C Cash Flow Report
- Arovella receives R&D tax rebate of $4.03 million
Later from Arovella Therapeutics
All Arovella Therapeutics news releasesFollow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics